Zurück zu Ihrem Suchergebnis

Beschreibung

An S100P-derived peptide based competitive antagonist for receptor for advanced glycation end product (RAGE). Shown to disrupt the interaction between RAGE and its ligands, such as S100P, S100A4 and HMGB-1 in binding assays and in multiple cancer cell lines (~2 µ,M). Also, blocks RAGE-dependent NF-kB activation in MPanc96, MOH and HPAF II tumor cell lines. Systemic administration of RAP also diminishes NF-kB signaling in vivo and significantly reduces glioma tumor growth in murine models.